As companies race to deploy AI, cautious ones are also racing to deploy guardrails and frameworks around the technology.
Glioblastoma is an aggressive and difficult-to-treat cancer, with median survival of just 15 months and fewer than 7% of patients surviving beyond five years. Clinical trials in GBM have a failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback